Tryptamine Microbiota-Deregulated Aminoacyl-tRNA Biosynthesis
A Conceptual Evolution of the Role of Microbiota Tryptamine in Human Diseases
- 1st Edition - May 31, 2024
- Imprint: Academic Press
- Author: Elena L. Paley
- Language: English
- Paperback ISBN:9 7 8 - 0 - 4 4 3 - 2 8 8 3 0 - 2
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 2 8 8 3 1 - 9
Tryptamine Microbiota-Deregulated Aminoacyl-tRNA Biosynthesis: A Conceptual Evolution of the Role of Microbiota Tryptamine in Human Diseases provides a detailed invest… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteTryptamine Microbiota-Deregulated Aminoacyl-tRNA Biosynthesis: A Conceptual Evolution of the Role of Microbiota Tryptamine in Human Diseases provides a detailed investigation into tryptamine, its underlying mechanisms, and metabolism across multiple diseases. The book explores key concepts of tryptamine, its biosynthetic pathways, and its influence in disease, specifically focusing on the Alzheimer’s disease-associated gut bacterial sequence (ADAS). Various neurodegenerative conditions are covered alongside cancer, diabetes, infections, and chromosomal aberrations. Additionally, a chapter on gut tryptamine in domestic and agricultural animals is included. The book closes with case studies involving FDG-PET imaging in the context of tryptamine-treated mouse models and Alzheimer’s disease patients.
This book elucidates the implications of the gut microbiota-mediated tryptamine metabolism for human health, sharing insights into disease etiology, mechanisms, testing, prevention, and treatment. It is an ideal reference for researchers across the biomedical sciences.
This book elucidates the implications of the gut microbiota-mediated tryptamine metabolism for human health, sharing insights into disease etiology, mechanisms, testing, prevention, and treatment. It is an ideal reference for researchers across the biomedical sciences.
- Provides a detailed investigation into tryptamine and its role in human health
- Explores the relationship between microbiome tryptamine metabolome and a range of diseases, including diabetes, cancer, Alzheimer’s disease and Parkinson’s disease
- Considers the role of tryptamine in cell death and the impairment of genome activities
- Paves the way for advances in disease prevention and treatment pathways
Researchers working across the biosciences in the fields of molecular biology, biochemistry, pharmacology, gastroenterology, neurology, and endocrinology
- Cover image
- Title page
- Table of Contents
- Copyright
- About the author
- Preface
- Chapter 1. Introduction
- 1. Modeling cell death and neurodegenerative diseases with human gut metabolite tryptamine inhibiting tryptophanyl-tRNA synthetase (Paley model)
- 2. Pollen microbiota and tryptamine in pollen and honey
- 3. Tryptamine-related pathways and diseases
- 4. ADAS in diseases
- 5. Bidens pilosa, obesity, amyotrophic lateral sclerosis, and tryptamine
- 6. Aminoacyl-tRNA biosynthesis pathway deregulation in different diseases
- 7. Conceptual and methodological pitfalls
- Chapter 2. Human gut microbial metabolite tryptamine inducing neurodegeneration causes chromosome and genome instability
- 1. Introduction
- 2. Experimental procedures
- 3. Experimental data
- 4. Discussion
- 5. Conclusions
- Chapter 3. Mutagenicity and genotoxicity of naturally occurring tryptamines and their principal metabolites
- 1. Nitrosation and mutagenesis of tryptamines
- 2. Tryptamines: Covalent DNA binding, cytotoxicity, DNA synthesis inhibition, and chromosomal aberrations
- 3. Genotoxicity of tryptophol and candidiasis
- 4. Role of tryptamine in cancer: Chromosomal aberrations and microbial internalization
- 5. Conclusions
- Chapter 4. Abundant urinary tryptamine as an indicator of urinary tract infection and nosocomial infections
- 1. Urinary tryptamines in normal subjects, patients with rheumatoid arthritis and other diagnoses
- 2. Urinary tryptamine and serotonin metabolite 5-HIAA: Comparison
- 3. Concluding remarks and new interpretations
- Chapter 5. Proteus mirabilis, diseases, and tryptamine
- 1. Biology and pathogenesis of Proteus mirabilis
- 2. Proteus mirabilis and cancer
- 3. Proteus mirabilis in rheumatoid arthritis
- 4. Proteus mirabilis in Parkinson's disease
- 5. Proteus mirabilis in diabetes
- 6. UTI and asymptomatic bacteriuria in aging and dementia
- 7. Proteus mirabilis and tryptamine in inflammatory bowel disease
- 8. Proteus mirabilis in vulvovaginitis in girls aged 2–12 years
- 9. Proteus mirabilis in prostatitis
- 10. Proteus mirabilis in food poisoning and diarrhea
- 11. Proteus mirabilis in vertebral osteomyelitis
- 12. Conclusions: Prodrome, ASB, and tryptamine
- Chapter 6. Microbial tryptophan metabolites in cancer and leishmaniasis
- 1. Down-regulation of gut microbial tryptophan metabolites in melanoma
- 2. Tryptamine affects Leishmania
- 3. Association between leishmaniasis and malignant disorders and misdiagnosis
- 4. Leishmaniasis: Epidemiological situation and transmission
- 5. Leishmania infections and host genes
- 6. Leishmaniasis and dysbiosis
- 7. Intracellular bacteria in protozoa
- 8. Conclusions
- Chapter 7. The effect of human microbial metabolome on multisensory integration in aging and neurodegenerative diseases
- 1. Sensory system and cognitive impairment
- 2. Tryptamine, aminoacyl-tRNA synthetases and sensory system
- 3. Vestibular and hearing systems
- 4. Vision (eye) and touch/tactile (skin)
- 5. Olfaction, nasal, skin (tactile, touch), and nociception (pain) microbiota
- 6. Taste (gustatory, tongue), saliva, IBS, and IBD
- 7. Sensory system and tryptophan/tryptamine in diabetes
- 8. Mosaicism, diabetes, and retinopathy
- 9. Sensory system and vagus nerve
- 10. Conclusions
- Chapter 8. Retinitis pigmentosa (RP): RP-causative gene mutations, RP-related gene mutations, mosaicism, and gut microbiome
- 1. Background
- 2. Retinitis pigmentosa: Autosomal gene mutations, HARS and mosaicism
- 3. X-linked RP
- 4. Mosaicism in X-linked RP
- 5. Tryptamine(s) target retinal cells and is associated with vitamin A plasma status
- 6. Medical conditions associated with retinopathy and RP
- 7. Gut microbiota and RP
- 8. Conclusive remarks
- Chapter 9. The tRNA aminoacylation interference in diseases
- 1. Regulation of aminoacyl-tRNA biosynthesis pathway by gut microbiota metabolome
- 2. Mutations in genes encoding human ARSs
- 3. ARSs in cancers and viral infections
- 4. Stress, gut viruses, tryptamine, and aminoacyl-tRNA biosynthesis
- 5. Conclusions
- Chapter 10. Tryptamine interfere with cytochrome P450
- 1. Role of cytochrome P450 and tryptamine involvement
- 2. CYP enzymes inhibited by tryptamine
- 3. CYP1A1, CYP1A2, and CYP1B1 gene expression upregulation by tryptamine
- 4. Conclusions
- Chapter 11. Discovery of Alzheimer's disease-associated sequence and Caudoviricetes prophage markers in metagenomics of type 2 diabetes and associated medical conditions
- 1. Alzheimer's disease, type 2 diabetes, AD-associated sequence, and tryptamine
- 2. Analysis of Chinese cohort with T2D
- 3. Analysis of European study with T2D or prediabetes
- 4. ADAS sequence in rheumatoid arthritis/ankylosing spondylitis, association with diabetes
- 5. ADAS and tryptamine in obesity and after weight-loss intervention
- 6. ADAS and Caudoviricetes prophage in preterm delivery in pregnancy
- 7. ADAS in Crohn's disease (CD)
- 8. Bacteriophages, prophages, and tryptamine
- 9. Tryptamine as a marker in metabolomics of diabetes and related medical conditions
- 10. Conclusive remarks with numbers
- Chapter 12. Tryptamine, ADAS and microbiome in Parkinson's disease
- 1. Tryptamine and its metabolites in Parkinson's disease (PD)
- 2. Tryptamine-induced Freezing of Gait (FoG)
- 3. Human gut microbiome, vagus nerve and ADAS in Parkinson's disease (PD)
- 4. Dementia in PD
- 5. Parkinson's disease, gut microbiome, plasmids and bacteriophages
- 6. PD medications l-DOPA and carbidopa, and tryptamine production
- 7. Conclusions
- Chapter 13. Microbial ADAS and tryptamine in domestic and agricultural animals
- 1. ADAS in piglet and chicken
- 2. Tryptamine and other biogenic amines in piglets and chickens
- 3. Tryptamine in horses
- 4. Tryptamine in dogs and cats
- 5. Tryptamine in cattle
- 6. Animal feeding with tryptamine
- 7. Conclusions
- Chapter 14. Tryptamine, stem cell/progenitor protein biosynthesis, and aminoacyl-tRNA biosynthesis
- 1. Tryptamine, tryptophan, TrpRS, and stem cells
- 2. Tryptophan and tryptamine derivatives regulate neurogenesis
- 3. Tryptamine metabolite indole-3-acetic acid in neurodegenerative diseases
- 4. Conclusions
- Chapter 15. Tryptamine metabolite indole-3-acetic acid in neurodegenerative diseases and other conditions
- 1. Biological activities of indole-3-acetic acid
- 2. Indole-3-acetic acid in diseases and medical conditions
- 3. Conclusions
- Chapter 16. FDG-PET: Tryptamine-treated mouse model and Alzheimer's disease patients. Conceptual evolution of microbiota tryptamine role in human diseases
- 1. Tryptamine, glucose, lactic acid, brain FDG-PET imaging, and Glut1 receptor
- 2. Tryptamine, glucose uptake, GLUT1 and CYP enzymes in cells from Alzheimer' disease patients
- 3. Tryptamine in the models of autoimmune diseases lupus and multiple sclerosis
- 4. Tryptamine biotransformation
- 5. Conclusions
- Chapter 17. Epilepsy, tryptamine-induced seizures, malfunction of ion channels, electrolyte abnormalities and antibiotic resistance
- 1. Epilepsy and Alzheimer's disease relation
- 2. Tryptamine-induced seizures in pharmacological tests
- 3. Serotonin abnormalities in sudden unexpected death in epilepsy (SUDEP) and sudden infant death syndrome (SIDS)
- 4. Malfunction of ion channels in epilepsy and in tryptamine models
- 5. Conclusions: Antibiotic-induced seizures, tryptamine neurotoxicity, prophage, antibiotic resistance, NQR, iron
- Chapter 18. Conclusions
- Index
- Edition: 1
- Published: May 31, 2024
- Imprint: Academic Press
- No. of pages: 350
- Language: English
- Paperback ISBN: 9780443288302
- eBook ISBN: 9780443288319
EP
Elena L. Paley
Dr. Paley is Cofounder of the nonprofit Stop Alzheimers Corp and Founder of Expert Biomed, Inc. She holds a PhD degree in biology with specialization in molecular biology from the Engelhardt Institute of Molecular Biology of the Russian Academy of Sciences in the Laboratory of Lev L. Kisselev. Dr. Paley’s research focuses mainly on protein biosynthesis in biology and diseases and is conducted in collaboration with Harvard University, Brandeis University, the University of Miami, Tel Aviv University, the Institut des Vaisseaux et du Sang (Paris, France), and the University of Texas at San Antonio. She is Adjunct Professor at Nova Southeastern University, FL, United States, and is inventor in patents issued and pending. Dr. Paley has previously published 4 books with Elsevier.
Affiliations and expertise
Adjunct Professor at Nova Southeastern University, FL,, USARead Tryptamine Microbiota-Deregulated Aminoacyl-tRNA Biosynthesis on ScienceDirect